Фоновый узор

Belara 2 mg/0,03 mg comprimidos recubiertos con pelicula

О препарате

Introduction

Package Leaflet: Information for the User

Belara 2 mg/0.03 mg Film-Coated Tablets

ethinylestradiol/chlormadinone acetate

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you experience. The final part of section 4 includes information on how to report these side effects.

Important information about combined hormonal contraceptives (CHCs):

  • They are one of the most reliable reversible contraceptive methods if used correctly.
  • They slightly increase the risk of suffering a blood clot in veins and arteries, especially in the first year or when restarting use of a combined hormonal contraceptive after a break of 4 weeks or more.
  • Be aware and consult your doctor if you think you may have symptoms of a blood clot (see section 2 “Blood clots”)

Read this leaflet carefully before you start taking this medicine, because it contains important information for you.

-Keep this leaflet, as you may need to read it again.

If you have any further questions, ask your doctor or pharmacist.

-This medicine has been prescribed for you only. Do not pass it on to others even if their symptoms are the same. It may harm them.

-If you experience any side effects, talk to your doctor or pharmacist. See section 4.

1.What Belara is and what it is used for

2.What you need to know before you start taking Belara

3.How to take Belara

4.Possible side effects

5.Storage of Belara

6.Contents of the pack and additional information

1. What is Belara and how is it used

Belara is an oral hormonal contraceptive. If this type of hormonal contraceptive contains two hormones, such as Belara, it is also known as a "combined hormonal contraceptive" (CHC). The 21 tablets in the blister pack for a cycle contain the same amount of both hormones, so Belara is also known as a "monophasic preparation".

Hormonal contraceptives like Belara will not protect you against HIV (AIDS) or other sexually transmitted diseases. Only condoms can help with this.

2. What you need to know before starting to take Belara

General Considerations

Before starting to use Belara, you should read the information about blood clots in section 2. It is particularly important that you read the symptoms of a blood clot (see section 2 “Blood Clots”).

Before starting to take Belara, your doctor will perform a general examination and a gynecological examination, rule out pregnancy, and, taking into account the contraindications and precautions, decide if Belara is suitable for you. These medical examinations must be performed annually while you are taking Belara.

Do not take Belara

You should not use Belara if you have any of the conditions listed below. Inform your doctor if you have any of the conditions listed below. Your doctor will discuss with you what other form of contraception would be more suitable.

  • If you are allergic to the active ingredients or to any of the other components of this medication (including in section 6);

-If you have (or have had at any time) a blood clot in a vein of the legs (deep vein thrombosis, DVT), in the lungs (pulmonary embolism, PE) or in other organs;

-If you present the initial symptoms of thrombosis, inflammation of the veins or embolism, such as the appearance of a brief stabbing pain, chest pain or pressure in the chest;

  • If you know that you have a disorder that affects blood clotting: for example, protein C deficiency, protein S deficiency, antithrombin III deficiency, factor V Leiden or antiphospholipid antibodies;
  • If you need surgery or if you spend a lot of time without standing up (see section “Blood Clots”);

-If you have diabetes and present significant fluctuations in blood sugar levels;

  • If you have uncontrolled high blood pressure or that increases significantly (constantly values above 140/90 mmHg);
  • If you have ever had a heart attack or a stroke;
  • If you have (or have had at any time) angina pectoris (a condition that causes severe chest pain and may be the first sign of a heart attack) or a transient ischemic attack (TIA, temporary symptoms of a stroke);
  • If you have any of the following diseases that may increase your risk of forming a blood clot in the arteries:
    • severe diabetes with vascular damage
    • very high blood pressure
    • very high levels of fat in the blood (cholesterol or triglycerides)
    • a condition called hyperhomocysteinemia
  • Si have (or have had at any time) a type of migraine called “migraine with aura”;
  • If you have liver inflammation (e.g., due to a virus) or jaundice, as long as your liver values have not returned to normal;
  • If you have generalized itching or have alterations in bile flow and especially during a previous pregnancy or during hormone treatment;
  • If your bilirubin (a product of blood pigment degradation) in the blood is increased, for example by a congenital excretion disorder (Dubin-Johnson syndrome or Rotor syndrome);
  • if you have meningioma or have ever been diagnosed with meningioma (a generally benign tumor of the tissue layer between the brain and the skull);
  • if you have a liver tumor or have had one in the past;
  • If you have severe stomach pain, liver enlargement or signs of internal bleeding in the abdomen;
  • If you have porphyria (a disorder of blood pigment metabolism), whether or not it is the first time.
  • If you have or have had or are suspected to have any malignant tumor that depends on hormone action, e.g., breast cancer or uterine cancer;
  • If you have severe lipid metabolism disorders.
  • If you have pancreatitis (inflammation of the pancreas) or a history of the same, in the case of being associated with severe hypertriglyceridemia (very high levels of triglycerides in the blood);

-If you have frequent or persistent episodes of severe unusual headaches;

  • If you have sudden changes in perception (vision or hearing);

-If you present changes in movement (particularly signs of paralysis).

  • If you observe worsening of seizures;
  • If you have severe depression;
  • If you have a certain type of hearing loss (otosclerosis) that worsened during previous pregnancies;
  • If you have had amenorrhea (absence of menstruation) due to an unknown cause;
  • If you present an abnormal thickening of the uterine mucous membranes (endometrial hyperplasia);.
  • If you have unjustified vaginal bleeding.

Do not use Belara if you have hepatitis C and are taking medications that contain ombitasvir/paritaprevir/ritonavir and dasabuvir, glecaprevir/pibrentasvir or sofosbuvir/velpatasvir/voxilaprevir (see also section Other Medications and Belara).

If you develop any of these conditions during the administration of Belara, you should stop taking Belara immediately. And inform your doctor immediately/notify your doctor.

You should not take Belara, or you should stop taking it immediately, if you have a high risk factor or multiple risk factors for arterial or venous thrombosis (see section 2).

Warnings and Precautions

Consult your doctor or pharmacist before starting to use Belara.

When to consult a doctor?

Seek urgent medical assistance

  • if you notice possible signs of a blood clot that may mean you are suffering from a blood clot in the leg (i.e., deep vein thrombosis), a blood clot in the lung (i.e., pulmonary embolism), a heart attack or a stroke (see section “Blood Clots” below).

For a description of the symptoms of these serious adverse effects, see “How to recognize a blood clot”.

Inform your doctor if you suffer from any of the following conditions.

  • If you smoke, as tobacco increases the risk of serious heart and blood vessel side effects with the use of combined hormonal contraceptives. This risk increases with age and with tobacco consumption. It affects especially women over 35 years old. Smoking women over 35 years old should use other methods of contraception.

If the condition develops or worsens while using Belara, you should also inform your doctor:

  • If you suffer from angioedema symptoms such as facial swelling, tongue and/or throat swelling, and/or difficulty swallowing or urticaria with possible difficulty breathing, contact a doctor immediately. Estrogen-containing products can cause or worsen the symptoms of hereditary and acquired angioedema;
  • If you have high blood pressure, abnormally high levels of lipids in the blood, obesity or diabetes (see also section 2). In this case, the risk of serious side effects associated with combined hormonal contraceptives (such as myocardial infarction, embolism, stroke or liver tumors) increases;
  • If you have Crohn's disease or ulcerative colitis (chronic inflammatory bowel disease);
  • If you have systemic lupus erythematosus (LES, a disease that affects your natural defense system).
  • If you have hemolytic uremic syndrome (HUS, a disorder of blood clotting that causes kidney insufficiency);
  • If you have sickle cell anemia (a hereditary disorder of red blood cells);
  • If you have high levels of fat in the blood (hypertriglyceridemia) or have a known family history of this condition. Hypertriglyceridemia has been associated with an increased risk of pancreatitis (inflammation of the pancreas);
  • If you need surgery or spend a lot of time without standing up (see section “Blood Clots”);
  • If you have recently given birth, you are at a higher risk of blood clots. You should ask your doctor when you can start taking Belara after childbirth.
  • If you have superficial vein inflammation that is under the skin;
  • If you have varicose veins.

BLOOD CLOTS

The use of a combined hormonal contraceptive like Belara increases your risk of suffering a blood clot compared to not using it. In rare cases, a blood clot can block blood vessels and cause serious problems.

Blood clots can form:

  • in veins (which is called “deep vein thrombosis”, “venous thromboembolism” or VTE).
  • in arteries (which is called “arterial thrombosis”, “arterial thromboembolism” or ATE).

The recovery of blood clots is not always complete. In rare cases, there may be long-lasting or even fatal effects.

It is essential to remember that the overall risk of a harmful blood clot due to Belara is small.

HOW TO RECOGNIZE A BLOOD CLOT

Seek urgent medical assistanceif you notice any of the following signs or symptoms.

Do you experience any of these symptoms?

What could you be suffering from?

  • Swelling of a leg or foot or along a vein of the leg or foot, especially when accompanied by:
  • Pain or sensitivity in the leg, which may only be noticeable when standing up or walking
  • Increased temperature in the affected leg
    • Change in skin color of the leg, p.e.g. if it becomes pale, red or blue

Deep vein thrombosis

  • Sudden shortness of breath without a known cause or rapid breathing
  • Sudden coughing without a clear cause, which may bring up blood
  • Severe chest pain that may worsen with deep breathing
  • Intense dizziness or disorientation
  • Irregular or rapid heartbeats
  • Severe stomach pain

If you are unsure, consult a doctor, as some of these symptoms such as coughing or shortness of breath can be confused with a milder condition such as a common cold.

Pulmonary embolism

Symptoms that occur more frequently in one eye:

  • Immediate loss of vision, or
  • Blurred vision without pain, which may progress to loss of vision.

Retinal vein thrombosis (blood clot in the eye)

  • Chest pain, discomfort, pressure, or heaviness
  • Sensation of fullness or indigestion
  • Sensation of oppression or plenitude in the chest, arm, or under the sternum
  • Upper body discomfort that radiates to the back, jaw, throat, arm, and stomach
  • Sweating, nausea, vomiting, or dizziness
  • Extreme weakness, anxiety, or shortness of breath
  • Irregular or rapid heartbeats

Heart attack

  • Sudden weakness or numbness on one side of the body, especially in the face, arm, or leg
  • Sudden confusion, difficulty speaking or understanding
  • Sudden difficulty seeing in one eye or both eyes
  • Sudden difficulty walking, dizziness, loss of balance, or coordination
  • Sudden severe headache
  • Loss of consciousness or fainting, with or without convulsions

Sometimes the symptoms of a stroke may be brief, with almost immediate and complete recovery, but you should still seek medical assistance as you may be at risk of another stroke.

Stroke

  • Swelling and slight blue discoloration of a limb
  • Severe stomach pain (abdominal pain)

Blood clots that block other blood vessels

BLOOD CLOTS IN A VEIN

What can happen if a blood clot forms in a vein?

  • The use of combined hormonal contraceptives has been associated with an increased risk of blood clots in veins (venous thrombosis). However, these adverse effects are rare. They occur more frequently in the first year of use of a combined hormonal contraceptive.
  • If a blood clot forms in a vein of the leg or foot, it may cause deep vein thrombosis (DVT).
  • If a blood clot breaks loose from the leg and lodges in the lung, it may cause a pulmonary embolism.
  • In very rare cases, a blood clot can form in a vein of another organ, such as the eye (retinal vein thrombosis).

When is the risk of a blood clot in a vein higher?

The risk of a blood clot in a vein is higher during the first year in which you take a combined hormonal contraceptive for the first time. The risk may be higher also if you start taking a combined hormonal contraceptive again (the same medication or a different medication) after a break of 4 weeks or more.

After the first year, the risk decreases, but it is always slightly higher than if you were not taking a combined hormonal contraceptive.

When you stop taking Belara, your risk of a blood clot returns to normal in a few weeks.

What is the risk of a blood clot?

The risk depends on your natural risk of VTE and the type of combined hormonal contraceptive you are taking.

The overall risk of a blood clot in the leg or lung (DVT or PE) with Belara is small.

  • Of every 10,000 women who do not use a combined hormonal contraceptive and are not pregnant, 2 will develop a blood clot in a year.
  • Of every 10,000 women who use a combined hormonal contraceptive containing levonorgestrel or noretisterone or norgestimato, 5-7 will develop a blood clot in a year.
  • We do not yet know how the risk of a blood clot compares with Belara and a combined hormonal contraceptive containing levonorgestrel.
  • The risk of a blood clot will depend on your personal history (see “Factors that increase your risk of a blood clot” below).

Risk of a blood clot in a year

Women whodo not usea combined hormonal contraceptive and are not pregnant

About 2of every 10,000 women

Women who use a combined hormonal contraceptive that containslevonorgestrel, noretisterone or norgestimato

About 5-7of every 10,000 women

Women who use Belara

We do not yet know

If you notice an increase in the frequency or intensity of migraine attacks during Belara administration (which may indicate a change in blood supply to the brain), consult your doctor as soon as possible, who may advise you to stop taking Belara immediately.

Factors that increase your risk of a blood clot in a vein

The risk of having a blood clot with Belara is small, but some conditions increase the risk. Your risk is higher:

  • If you are overweight (body mass index (BMI) greater than 30 kg/m2).
  • If one of your close relatives has had a blood clot in the leg, lung, or other organ at a young age (i.e., before about 50 years old). In this case, you may have a hereditary disorder of blood clotting.
  • If you need surgery or spend a lot of time without standing up due to an injury or illness or if you have a leg cast. You may need to stop taking Belara for several weeks before the surgery or while you have less mobility. If you need to stop taking Belara, ask your doctor when you can start using it again.
  • With increasing age (especially over about 35 years old).
  • If you have given birth recently.

The risk of a blood clot increases the more conditions you have.

Air travel (more than 4 hours) may temporarily increase the risk of a blood clot, especially if you have any of the other risk factors listed.

It is essential to inform your doctor if you suffer from any of the conditions above, even if you are unsure. Your doctor may decide that you need to stop taking Belara.

If any of the conditions above change while you are using Belara, for example, a close relative experiences a blood clot without a known cause or you gain a lot of weight, inform your doctor.

BLOOD CLOTS IN AN ARTERY

What can happen if a blood clot forms in an artery?

Like a blood clot in a vein, a blood clot in an artery can cause serious problems. For example, it can cause a heart attack or a stroke.

Factors that increase your risk of a blood clot in an artery

It is essential to note that the risk of a heart attack or stroke due to Belara is very small, but it may increase:

  • With age (over about 35 years old).
  • If you smoke.When using a combined hormonal contraceptive like Belara, you are advised to quit smoking. If you are unable to quit smoking and are over 35 years old, your doctor may advise you to use a different type of contraception.
  • If you are overweight.
  • If you have high blood pressure.
  • If one of your close relatives has had a heart attack or stroke at a young age (less than about 50 years old). In this case, you may also be at higher risk of having a heart attack or stroke.
  • If you or one of your close relatives has high levels of fat in the blood (cholesterol or triglycerides).
  • If you have migraines, especially migraines with aura.
  • If you have a heart problem (valve disorder, arrhythmia called atrial fibrillation).
  • If you have diabetes.

If you have one or more of these conditions or if any of them are particularly severe, your risk of a blood clot may be increased even further.

If any of the conditions above change while you are using Belara, for example, you start smoking, a close relative experiences a blood clot without a known cause, or you gain a lot of weight, inform your doctor.

Tumors

In some studies, a risk factor for cervical cancer (cervix) has been observed in women infected with a sexually transmitted virus (human papillomavirus) and who have been taking the pill for a long period. However, it is not clear to what extent these results may be due to other factors (e.g., multiple sexual partners, use of barrier methods of contraception).

Studies have shown a slight increase in the risk of breast cancer in women taking combined hormonal contraceptives.

During the 10 years following the interruption of use, of AHC, this risk returns gradually to the age-related risk. Since breast cancer is rare in women under 40 years old, the number of excess diagnoses of breast cancer in current and recent users of AHC is small compared to the overall risk of breast cancer.

In rare cases, benign liver tumors have been reported, and more rarely malignant liver tumors, with hormone treatment. These can cause a life-threatening internal hemorrhage. If you experience severe abdominal pain in the stomach that does not subside spontaneously, you should consult your doctor.

The use of chlormadinone acetate has been associated with the development of a generally benign tumor of the tissue layer between the brain and the skull (meningioma). The risk increases especially when used at high doses for a prolonged period (several years). If you are diagnosed with meningioma, your doctor will interrupt your treatment with Belara (see section “Do not take Belara”). If you notice symptoms such as changes in vision (e.g., double vision or blurred vision), loss of hearing or ringing in the ears, loss of smell, worsening headaches that last over time, loss of memory, seizures, or weakness in arms or legs, you should inform your doctor immediately.

Other pathologies

Mental disorders

Some women who use combined hormonal contraceptives, such as Belara, have reported depression or a depressive mood. Depression can be severe and sometimes may induce suicidal thoughts. If you experience mood changes and depressive symptoms, contact your doctor for additional medical advice as soon as possible.

Many users experience a slight increase in blood pressure during the use of combined hormonal contraceptives. If blood pressure increases significantly when taking Belara, you should consult your doctor, who will advise you to stop treatment and prescribe a medication to reduce blood pressure. Belara treatment can be resumed once blood pressure returns to normal values.

If you have had herpes gestational in a previous pregnancy, it may recur during the use of combined hormonal contraceptives.

If you have lipid metabolism disorders or have a family history, there is a higher risk of pancreatitis. If you experience acute or chronic liver function disorders, your doctor may advise you to stop taking Belara until liver function values return to normal. If you have had jaundice during a previous pregnancy or during the use of a combined hormonal contraceptive, and it recurs, your doctor will advise you to stop taking Belara.

If you are diabetic and your blood sugar levels are controlled, your doctor will monitor you closely while you are taking Belara. You may need to modify your diabetes treatment.

In rare cases, brown spots may appear on the skin (melasma), especially if they appeared during a previous pregnancy. If you know you are prone to it, you should avoid long periods of exposure to the sun or ultraviolet radiation while taking Belara.

Disorders that may be negatively affected

You will also need special medical supervision if you suffer from:

-epilepsy;

-multiple sclerosis;

-severe muscle cramps (tetany);

-migraine (see also section 2);

-asthma;

-heart or kidney disease (see also section 2);

-St. Vitus dance (chorea minor);

-diabetes (see also section 2);

-liver disease (see also section 2);

-lipid metabolism disorders (see also section 2);

-immune system disorders (including systemic lupus erythematosus);

-excessive obesity;

-high blood pressure (see also section 2);

-endometriosis (the tissue that lines the uterine cavity, called endometrium, is found outside this lining layer) (see also section 2);

-varicose veins or vein inflammation (see also section 2);

-blood clotting disorders (see also section 2);

-breast disease (mastopathy);

-benign tumors (fibroids) in the uterus;

-herpes gestational in a previous pregnancy;

-depression;

-chronic inflammatory bowel disease (Crohn's disease, ulcerative colitis).

Consult your doctor if you have, or have had, any of the conditions mentioned or if they occur during the administration of Belara.

Efficacy

If you do not take the contraceptive regularly, experience vomiting or diarrhea after administration (see section 3), or take other medications simultaneously (see section 2), the efficacy of the contraceptive may be affected. In very rare cases, metabolic disorders may affect the contraceptive efficacy.

Even when taking hormonal contraceptives correctly, they do not guarantee that you will not become pregnant.

Irregular bleeding

Particularly in the first months of use of hormonal contraceptives, irregular vaginal bleeding (intermenstrual bleeding or spotting) may occur. If the bleeding persists or occurs for 3 months, or recurs after several consecutive cycles, consult your doctor.

Spotting (spotting) may also be a sign of reduced contraceptive efficacy. In these cases, bleeding may not occur after taking Belara for 21 days. If you have taken Belara following the instructions described in section 3, it is unlikely that you are pregnant. If you have not taken Belara following these instructions before the first absence of bleeding due to deprivation, you should rule out pregnancy before continuing with its use.

Children and adolescents

Belara is only indicated after menarche. The safety and efficacy of Belara have not been established in adolescents under 16 years old. There are no data.

Older patients

Belara is not indicated after menopause.

Other medications andBelara

Inform your doctor or pharmacist if you are using or have used recentlyor may need to use anyother medication.

Do not use Belara if you have hepatitis C and are taking medications that contain ombitasvir/paritaprevir/ritonavir and dasabuvir, glecaprevir/pibrentasvir or sofosbuvir/velpatasvir/voxilaprevir, as these medications may cause increases in liver function parameters in the blood (elevated liver enzyme ALT).

Your doctor will prescribe another type of contraceptive before starting treatment with these medications.

Belara can be restarted approximately 2 weeks after completing this treatment. See section “Do not take Belara”.

  • Some medications may have some influence on the blood levels of Belara and make itless effective in preventing pregnancy, or may produce unexpected bleeding. These include medications used to treat:
  • epilepsy (such as barbiturates, carbamazepine, phenytoin, topiramate, felbamate, oxcarbazepine, barbexaclona, primidone),
  • tuberculosis (e.g. rifampicin, rifabutin),
  • sleep disorders (modafinil),
  • infections with HIV and hepatitis C viruses (the so-called protease inhibitors and non-nucleoside reverse transcriptase inhibitors, such as ritonavir, nevirapine, efavirenz),
  • fungus infections (griseofulvin),
  • high blood pressure in the pulmonary blood vessels (bosentan),
  • preparations containing St. John's Wort (Hypericum perforatum). If you need to take preparations containing St. John's Wort while taking Belara, you should consult your doctor first.

Medications that stimulate intestinal movement (e.g. metoclopramide) and activated charcoal may affect the absorption of Belara's active ingredients and reduce their effects.

During treatment with these medications, you should use additional barrier methods of contraception (e.g. condoms). These barrier methods of contraception should be used throughout the duration of concomitant treatment and for 28 days after treatment completion. If concomitant treatment with another medication is prolonged beyond the days for which the current package of combined hormonal contraceptives is intended, you should start with the next package of Belara without leaving the usual rest period.

You should not take St. John's Wort preparations while taking Belara.

If you need to follow a prolonged treatment with the previously mentioned active substances, you should use non-hormonal methods of contraception. Consult your doctor or pharmacist.

The interactions between Belara and other medications may increase or intensify the adverse effects of Belara. The following medications may negatively affect the tolerability of Belara:

-ascorbic acid (a preservative, also known as vitamin C),

-paracetamol (relieves pain and controls fever),

-atorvastatin (reduces high cholesterol levels),

-troleandomycin (an antibiotic),

-3. How to take Belara

Follow exactly the administration instructions of this medication as indicated by your doctor.In case of doubt, consult your doctor or pharmacist again.

Administration mode

Oral route.

How and when should you take Belara?

Remove the first tablet, choosing the one marked with the correct day of the week (e.g. "Dom" on Sunday) and swallow it without chewing. Then take another tablet every day following the direction of the arrow, if possible at the same time of day, preferably at night. If possible, the interval between the intake of tablets should always be 24 hours. The printed days on the blister pack allow you to check each day if you have already taken the tablet for that day.

Take one tablet daily for 21 consecutive days. Then follow a 7-day break. Normally, withdrawal bleeding, equivalent to menstrual bleeding, will start 2-4 days after taking the last tablet. After the 7-day break, continue taking the tablets from the next blister pack of Belara, whether or not bleeding has stopped.

When can you start taking Belara?

If you have not taken any hormonal contraceptives previously (during the last menstrual cycle)

Take your first Belara tablet on the first day of your next menstrual cycle.

Contraception begins on the first day of administration and continues during the 7-day break.

If your period has already started, take the first tablet on the 2nd-5th day of your period, regardless of whether bleeding has stopped or not. However, in this case, you must use additional barrier contraceptives during the first 7 days of administration (7-day rule).

If your period started more than 5 days ago, wait until the next period to start taking Belara.

If you have taken a previous combined hormonal contraceptive

Take all the tablets from the old blister pack following the usual schedule. You should start taking Belara the day after the usual break between tablet intake or the day after the last placebo tablet of your previous combined hormonal contraceptive.

If you have taken a hormonal contraceptive that only contains progestogens

If you are taking a hormonal contraceptive that only contains a progestogen, you may not have withdrawal bleeding equivalent to menstrual bleeding. In this case, take the first Belara tablet the day after taking the last mini-pill. In this case, you must take additional contraceptive measures during the first 7 days.

If you have previously used injectable hormonal contraceptives or implants

Take the first Belara tablet on the day of the implant removal or the day corresponding to the next injection. In this case, you must take additional contraceptive measures during the first 7 days.

If you have had a spontaneous or induced abortion in the first three months of pregnancy

After a spontaneous or induced abortion, you can start taking Belara immediately. In this case, you do not need to use any additional contraceptive method.

If you have given birth or had a spontaneous or induced abortion between the third and sixth month of pregnancy

If you are not breastfeeding, you can start taking Belara 21-28 days after delivery. You do not need to use any additional barrier contraceptive method.

However, if more than 28 days have passed since delivery, you must use additional barrier contraceptive methods during the first 7 days.

If you have already had sex, you must rule out pregnancy or wait until the next period before starting Belara.

Remember that you should not take Belara if you are breastfeeding (see section "Pregnancy and breastfeeding").

How long can you take Belara?

You can take Belara for as long as you want, as long as there are no risks to your health (see section 2). Once you stop taking Belara, your next cycle may be delayed by about a week.

What should you do if you experience vomiting or diarrhea while taking Belara?

If vomiting or diarrhea occurs within 4 hours of taking the tablets, it is possible that the absorption of Belara's active ingredients may be incomplete. This situation is similar to what happens if you forget to take a tablet and have to take a new tablet from a new blister pack immediately. If possible, take the new tablet before 12 hours from the last tablet intake and continue taking Belara following your usual schedule. If this is not possible or more than 12 hours have passed, follow the instructions in section 3. "If you forgot to take Belara" or contact your doctor.

If you take more Belara than you should

There is no evidence of severe toxicity symptoms after taking a large number of tablets in a dose. You may experience symptoms such as nausea, vomiting, and, particularly in the case of women, light vaginal bleeding. In this case, consult your doctor. If necessary, they will check your electrolytes and fluid balance, and liver function.

For overdose or accidental ingestion, consult your doctor or pharmacist immediately, or call the Toxicology Information Service, phone: 915620420, indicating the medication and the amount ingested.

If you forgot to take Belara

  • If you forgot to take a tablet at the usual time, take it as late as within 12 hours. In this case, no additional contraceptive methods are necessary and you can continue taking the tablets as usual.
  • If the interval isgreater than 12 hours, the contraceptive effect of Belara is not guaranteed. In this case, take the missed tablet immediately and continue taking Belara following your usual schedule. This may even mean taking 2 tablets on the same day. In this case, you must use additional contraceptive methods (e.g. condoms) during the next 7 days. If during these 7 days you finish the blister pack you started, begin taking the tablets from the next blister pack of Belara immediately, i.e. do not have a break between blister packs (7-day rule). You may not experience withdrawal bleeding until you finish the next blister pack. However, you may experience spotting (small drops or spots of blood) or intermenstrual bleeding.

The more tablets you forget, the greater the risk that the protection against pregnancy may be reduced. If you forgot one or more tablets in the first week and had sex in the week before forgetting the tablets, you must know that there is a risk of pregnancy. The same applies if you forgot one or more tablets and did not have bleeding in the next break period. In these cases, consult your doctor.

If you want to delay your menstrual period

Although not recommended, it is possible to delay your menstrual period (withdrawal bleeding) until the end of a new blister pack if you start taking a second blister pack instead of continuing with the break period between tablet intake. You may experience spotting (small drops or spots of blood) or intermenstrual bleeding during the use of the second blister pack. After the break period between tablet intake of 7 days, continue with the next blister pack.

You should ask your doctor for advice before deciding to delay your menstrual period.

If you want to change the first day of your menstrual period

If you take the tablets as instructed, your menstrual period/withdrawal bleeding will start during the break period between tablet intake. If you need to change that day, you can do so by shortening (but never lengthening) the break period between tablet intake. For example, if your break period between tablet intake starts on Friday and you want to change it to Tuesday (3 days earlier), you must start a new blister pack 3 days earlier than usual. If you make the break period between tablet intake too short (e.g. 3 days or less), you may not experience bleeding during this period. You may then experience spotting (small drops or spots of blood) or intermenstrual bleeding.

If you are unsure how to proceed, consult your doctor for advice.

If you interrupt treatment with Belara

When you stop taking Belara, your ovarian function will be completely restored and you may become pregnant.

If you have any other questions about the use of thismedication, ask your doctororpharmacist.

4. Possible Adverse Effects

Like all medicines,Belaracan cause side effects, although not everyone will experience them. If you experience any side effect, especially if it is severe and persistent, or if you have any health changes that you think may be related to Belara, consult your doctor.

Seek medical attention immediately if you experience any of the following angioedema symptoms: swelling of the face, tongue, and/or throat and/or difficulty swallowing or urticaria with possible difficulty breathing (see also the "Warnings and precautions" section).

All women taking combined hormonal contraceptives are at a higher risk of developing blood clots in the veins (venous thromboembolism (VTE)) or blood clots in the arteries (arterial thromboembolism (ATE)). For more detailed information on the different risks of taking combined hormonal contraceptives, see section2 "What you need to know before starting Belara".

The frequencies with which side effects have been reported are defined as follows:

Very common: may affectmore than 1 in 10 people

Nausea, vaginal discharge, menstrual cramps, amenorrhea.

Common:may affectup to 1 in 10 people

Depression, nervousness, irritability, dizziness, migraine (and/or worsening of these), visual disturbances, vomiting, acne, feeling of heaviness, abdominal pain, fatigue,fluid retention,weight gain, increased blood pressure.

Uncommon:may affectup to 1 in 100 people

Vaginal yeast infection, benign changes in breast tissue, hypersensitivity to the drug including skin allergic reactions, changes in blood lipids including increased triglycerides, decreased libido, stomach pain, intestinal sounds, diarrhea, pigmentation problems, brown spots on the face, hair loss, dry skin, tendency to sweat, back pain, muscle disorders, nipple discharge.

Rare:may affectup to 1 in 1,000 people

Vaginal inflammation, increased appetite, conjunctivitis, discomfort when wearing contact lenses, hearing loss, tinnitus, hypertension, hypotension, circulatory blockage, varicose veins, urticaria, eczema, skin inflammation, pruritus, worsening of psoriasis, excessive body or facial hair, breast enlargement, prolonged and/or increased menstrual bleeding, premenstrual syndrome (physical and emotional disorders before menstruation).

Life-threatening blood clots in a vein or artery, for example:

  • in a leg or foot (i.e., DVT).
  • in a lung (i.e., PE).
  • heart attack.
  • stroke.
  • transient ischemic attack (TIA) or temporary symptoms similar to a stroke.
  • blood clots in the liver, stomach/intestine, kidneys, or eye.

The risk of having a blood clot may be higher if you have any other condition that increases this risk (see section 2 for more information on conditions that increase the risk of blood clots and symptoms of a blood clot).

Very rare:may affect up to 1 in 10,000 people.

Erythema nodosum.

In addition, the following adverse reactions associated with the active ingredients ethinylestradiol and chlormadinone acetate have been reported in post-marketing experience: weakness and allergic reactions including deep skin layer inflammation (angioedema).

Combined hormonal contraceptives have also been associated with an increased risk of the following serious diseases and adverse effects:

  • venous and arterial thrombosis risk (see section 2)
  • bile duct disease risk (see section 2)
  • tumor risk (e.g., liver tumors, which in isolated cases have caused potentially fatal abdominal cavity hemorrhage, cervical cancer or breast cancer(see section 2),
  • emergence of chronic inflammatory bowel disease (Crohn's disease, ulcerative colitis,see section 2).

Read the information presented in section 2 carefully and, if necessary, consult your doctor immediately.

Reporting of adverse reactions

If you experience any type of adverse reaction, consult your doctor or pharmacist, even if it is a possible adverse reaction that does not appear in this leaflet. You can also report them directly through the Spanish System for the Pharmacovigilance of Medicinal Products for Human Use:https://www.notificaram.es. By reporting adverse reactions, you can contribute to providing more information on the safety of this medication.

5. Belara Storage

Keepthis medicationout of the sight and reach of children.

Do not store at a temperature above30°C.

Do not usethis medicationafter the expiration date that appears on the box and on the cycle blister (pack) after “CAD". The expiration date is the last day of the month indicated.

Medicines should not be disposed of through drains or in the trash. Dispose of packaging and medicines you no longer need at the SIGRE collection pointat the pharmacy. If in doubtask your pharmacist how to dispose of packaging and medicines you no longer need. By doing so, you will help protect the environment.

6. Contents of the packaging and additional information

Composition of Belara

  • The active ingredients are chlormadinone acetate and ethinylestradiol. Each film-coated tablet contains 2.0 mg of chlormadinone acetate and 0.030 mg of ethinylestradiol.
  • The other components are:

Core of the tablet: lactose monohydrate,cornstarch, povidone K 30, magnesium stearate.

Film coating of the tablet: hypromellose,lactose monohydrate, macrogol 6000, propylene glycol, talc, titanium dioxide (E 171),iron oxide red (E 172).

Appearance of the product and contents of the package

Belara is presented in blisters containing 21 film-coated tablets, round, pale pink, for one cycle per blister.

Packages:1x21, 3x21, 6x21, 13x21film-coated tablets.

Only some package sizes may be commercially marketed.

Holder of the marketing authorization and responsible for manufacturing

Holder of the marketing authorization:

Gedeon Richter Plc.

Gyömroi út 19-21

1103 Budapest

Hungary

Responsible for manufacturing

Gedeon Richter Plc.

Gyömroi út 19-21

1103 Budapest

Hungary

For more information about this medication, please contact the local representative of the marketing authorization holder.

Gedeon Richter Ibérica S.A.

Sabino Arana, 28 4º 2º

08028 Barcelona

+34 93 2034300

This medication is authorized in the member states of the European Economic Area with the following names:

GermanyBelara Filmtabletten

AustriaBelara – Filmtabletten

BelgiumBellina0,03mg/2 mg – Filmomhulde tabletten

SloveniaBelara0,03mg/2 mg filmsko obložene tablete

SpainBelara2 mg /0,03mg comprimidos recubiertos con película

FranceBelara comprimés pelliculés

ItalyBelara0,03mg/2 mg compresse rivestite con film

LuxembourgBellina0,03mg/2 mg – Filmomhulde tabletten

PortugalBelara 2 mg +0,03mg comprimidos

Last review date of this leaflet:February2023

For detailed and updated information about this medication, please visit the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/

Страна регистрации
Активное вещество
Требуется рецепт
Да
Производитель
Состав
Propilenglicol (0,093 mg mg), Alcohol etilico (etanol) (C.S. mg mg), Lactosa hidratada (68,97 mg mg), Lactosa hidratada (0,575 mg mg)
Информация носит справочный характер и не является медицинской рекомендацией. Перед приёмом любых препаратов проконсультируйтесь с врачом. Oladoctor не несёт ответственности за медицинские решения, принятые на основе этого контента.

Общайтесь с врачом онлайн

Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.

5.01 отзыв
Doctor

Анна Морет

Дерматологія18 лет опыта

Анна Морет — лікарка-дерматолог і дерматовенеролог із міжнародною сертифікацією. Спеціалізується на дерматології дорослих і дітей, венерології, естетичному догляді за шкірою та загальній медицині. Проводить онлайн-консультації, базуючись на доказовій медицині та індивідуальних потребах кожного пацієнта.

Сфера допомоги охоплює: • захворювання шкіри: екзема, акне, розацеа, дерматити, псоріаз • проблеми з волоссям і шкірою голови: випадіння волосся, лупа, себорейний дерматит • дитяча дерматологія — від новонароджених до підлітків • венерологія та інфекції, що передаються статевим шляхом (ІПСШ) • естетичні запити: вікові зміни шкіри, неінвазивні косметологічні процедури • алергічні реакції та підвищена чутливість шкіри • перевірка родимок, оцінка новоутворень, скринінг раку шкіри • поради щодо догляду за шкірою та підбір індивідуальної космецевтики

Поєднуючи дерматологію із загальноклінічним досвідом, Анна Морет надає всебічну допомогу, що охоплює як стан шкіри, так і супутні захворювання. Має сертифікацію Канадської ради естетичної медицини, що підтверджує міжнародний підхід до естетичної дерматології.

Записаться на онлайн-консультацию
5.01 отзыв
Doctor

Аліна Цуркан

Сімейна медицина12 лет опыта

Аліна Цуркан — ліцензована лікарка сімейної медицини в Португалії. Проводить онлайн-консультації для дорослих і дітей, допомагаючи пацієнтам у вирішенні широкого спектра щоденних медичних запитів з професійним підходом і увагою до деталей.

Звернутися можна з такими станами: • респіраторні інфекції: застуда, грип, бронхіт, пневмонія • Захворювання очей: кон’юнктивіт (інфекційний і алергічний) • ЛОР-захворювання: синусит, отит, тонзиліт • проблеми з травленням: гастрит, кислотний рефлюкс, синдром подразненого кишківника (СПК) • інфекції сечових шляхів та інші поширені інфекції • хронічні захворювання: артеріальна гіпертензія, діабет, порушення функції щитоподібної залози • головний біль і мігрень

Окрім лікування симптомів, Аліна Цуркан приділяє особливу увагу профілактиці та ранньому виявленню захворювань. Проводить планові огляди, надає медичні рекомендації, здійснює повторні консультації та виписує рецепти — з урахуванням індивідуальних потреб кожного пацієнта.

Її підхід — комплексний, уважний і адаптований до кожного етапу життя пацієнта: від гострих станів до довготривалого контролю здоров’я.

Записаться на онлайн-консультацию
5.09 отзывов
Doctor

Андрій Попов

Терапія6 лет опыта

Андрій Попов — ліцензований в Іспанії терапевт і фахівець із лікування болю. Проводить онлайн-консультації для дорослих, допомагаючи впоратися з хронічним і гострим болем, а також із широким спектром загальних медичних запитів.

Спеціалізується на діагностиці та лікуванні болю, що триває понад 3 місяці або суттєво знижує якість життя. Працює з такими станами, як: • хронічний біль будь-якого походження • мігрень і повторювані головні болі • біль у шиї, спині, попереку та суглобах • посттравматичний біль після травм, розтягнень або операцій • невропатичний біль, фіброміалгія, невралгії

Окрім знеболення, Андрій Попов допомагає пацієнтам у веденні загальних медичних станів, зокрема: • респіраторні інфекції (застуда, бронхіт, пневмонія) • артеріальна гіпертензія, порушення обміну речовин, цукровий діабет • профілактичні огляди та контроль загального стану здоров’я

Онлайн-консультація триває до 30 хвилин і включає детальний аналіз симптомів, рекомендації щодо обстежень, формування індивідуального плану лікування та подальший супровід за потреби.

Андрій Попов дотримується принципів доказової медицини, поєднуючи клінічний досвід із уважним і персоналізованим підходом до кожного пацієнта.

Записаться на онлайн-консультацию
5.01 отзыв
Doctor

Євген Яковенко

Загальна хірургія11 лет опыта

Євген Яковенко — ліцензований лікар-хірург і терапевт в Іспанії. Спеціалізується на загальній і дитячій хірургії, внутрішній медицині та лікуванні болю. Проводить онлайн-консультації для дорослих і дітей, поєднуючи хірургічну практику з терапевтичним супроводом.

Сфера медичної допомоги охоплює: • діагностику та лікування гострого й хронічного болю • перед- і післяопераційний супровід, оцінку ризиків, контроль стану • хірургічні захворювання: грижі, жовчнокам’яна хвороба, апендицит • консультації з дитячої хірургії: вроджені стани, дрібні втручання • травми: переломи, ушкодження м’яких тканин, обробка ран • онкохірургія: консультації, планування, супровід після лікування • внутрішні захворювання: патології серцево-судинної та дихальної систем • ортопедичні стани, реабілітація після травм • інтерпретація результатів візуалізації для хірургічного планування

Євген Яковенко активно займається науковою діяльністю та міжнародною співпрацею. Член Асоціації хірургів Німеччини (BDC), співпрацює з Асоціацією сімейних лікарів Лас-Пальмаса та Німецьким консульством на Канарських островах. Регулярно бере участь у міжнародних медичних конференціях і публікує наукові статті.

Поєднуючи багатопрофільний досвід із доказовою медициною, він надає точну та індивідуалізовану допомогу для пацієнтів із різними медичними запитами.

Записаться на онлайн-консультацию
Смотреть всех врачей

Следите за новостями и экономьте на услугах

Советы врачей, обновления платформы и скидки для подписчиков.

Следите за нами в соцсетях